GlobalData Plc

The total knee replacement market in North America, which covers Canada, Mexico, and the US, is set to rise from $3.63 billion in 2016 to around $4.2 billion by 2023, representing a compound annual growth rate of 2.2%, according to GlobalData, a recognized leader in providing business information and analytics.

The company’s latest report states that this modest growth will be driven by the growing prevalence of osteoarthritis, continued technological advancements in joint reconstruction surgeries, healthcare reform and a focus on economical modes of treatment.

Tobe Madu, MSc, Healthcare Analyst for GlobalData, explains: “There are multiple paths that the total knee replacement market could take as it develops. For example, investments could be made into expensive capital equipment such as robots, which will result in consistent, reproducible implant placement, less soft tissue damage, and shorter rehabilitation periods. This would lead to lower post-surgical costs.

“Additionally, there is a case to be made for custom implants leading to fewer complications and potentially reducing post-acute care costs. Further research will have to be carried out on the economics of each scenario and its ability to scale, and each specific geographical region will require a different approach.

Knee reconstruction is a fully mature market that has experienced no major innovation over the last decade other than incremental improvements. As health executives are scrutinizing purchases and using multiple channels to procure orthopedic devices at highly competitive prices, profit margins have been negatively affected, with global revenues falling in the large joint reconstruction space.

Madu continues: “A long-term foothold within the North American knee market hinges on how well companies can align themselves with the primary market force buffeting healthcare today: the need to deliver top-notch, cost-effective care.

“North America accounts for approximately 50% of the global knee reconstruction market therefore, given the heightened competitive pressures and shrinking reimbursement globally, the average selling price for total knee reconstruction implants is expected to decline. However, GlobalData believes that the revenue from increased procedure volume will make up for this loss.”

– Information based on GlobalData’s report: MediPoint: Total Knee Replacement – North America Analysis and Market Forecasts.

Related Intelligence

Want more Insight like this?

Our interactive subscription platform has the most comprehensive data and analysis in your industry.

Request a Demo

Related Consulting

How can we help your business?

Our consultants are skilled in every specialist market niche to deliver solutions specifically designed for your individual requirements.

Request a Callback

    Press Release Healthcare

    Late-stage CKD-induced comorbidity therapeutics market to reach $10.5bn by 2026

    Sales for chronic kidney disease (CKD)-induced hyperparathyroidism (HPT), hyperphosphatemia (HP), and hyperkalemia (HK) therapeutics were estimated to be $4.2bn across the seven major markets (7MM*) in 2016. This is expected to grow to $10.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 9.5%, according to GlobalData, a leading data and analytics company.

    Press Release Healthcare

    Majority of oncology clinical trials in China failed to meet enrolment targets

    The majority of oncology clinical trials in China that had a start date between 1 January 2012 and 31 December 2017 failed to meet the planned enrolment targets, according to GlobalData, a leading data and analytics company. The company identified and analyzed enrollment efficiencies of 324 clinical trials during the period and found that on...

    Press Release Healthcare

    Need for supportive care in oncology will increase during the next decade

    The need for effective supportive care in oncology will increase in the next decade as patients continue to live longer and cancer progresses to become more like a chronic disease. This includes the need for chemotherapy-related conditions, as chemotherapy will remain the backbone of cancer therapy for the foreseeable future, observes GlobalData, a leading data and analytics company.

    Press Release Healthcare

    World Cancer Day: What will 2018 mean for cancer research and treatment?

    The theme of this year’s World Cancer Day held on 4th February of “We can. I can.” aimed to reinforce the public message that all individuals and groups can play their part in reducing the global burden of cancer. Indeed in recent years many events have involved collaborations between traditional drug developers, cancer treatment professionals and those of varying disciplines. Examples include the IBM Watson supercomputer which is helping physicians make treatment decisions and the development of other databases such as ASCO’s CancerLinQ which assists oncologists in monitoring and analyzing patient data.

    Press Release Healthcare

    Melanoma sales are projected to rise to $5.5bn in 2026

    The value of the melanoma market was estimated to be $3.3bn across the seven major markets (7MM*) in 2016. This is expected to grow to $5.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 5.3%, according to GlobalData, a leading data and analytics company.

Media Enquiries

If you are a member of the press or media and require any further information, please get in touch, as we’re very happy to help.

Emailpr@globaldata.com
PhoneEMEA: +44 207 832 4399
PhoneAPAC: +91 40 6616 6809
Onlinecontact online

56% of #consumers are concerned about the impact of diet. Join us for more insight @incosmetics #cosmetics #trends… https://t.co/wJOJOqYIJF